NASDAQ$KYMR
Kymera Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Kymera Therapeutics reported Q3 2025 revenue of $2.8M, a net loss of $82.2M, diluted EPS of $-0.94.
For Q3 2025, Kymera Therapeutics reported Revenue was $2.8M, net loss was $82.2M, diluted EPS was $-0.94. The filing discusses operating performance, liquidity, and outlook in MD&A.
- Revenue $2.8M for Q3 2025.
- Net loss $82.2M.
- Diluted EPS $-0.94.
Headline financials
Revenue & EPS history
Kymera Therapeutics · Revenue · Quarterly
$2.76M
Forward guidance
Outlook focuses on cash runway, pipeline milestones, and cost discipline toward profitability.
Tailwinds
- Cash and equivalents support operations into upcoming milestones.
- Collaboration, licensing, or product pipeline progress noted in MD&A.
Headwinds
- Ongoing operating losses and R&D spend pressure near-term earnings.
- Financing, dilution, or partnership timing may affect liquidity.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+1.0%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.3%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+23.5%
Q3 2023
Best reaction
-32.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | +1.5% | -0.2% | |
| Q4 2025 | +4.8% | -4.8% | -13.8% | |
| Q3 2025 | +0.3% | -1.8% | +10.9% | |
| Q1 2025 | -2.0% | -3.3% | +54.8% | |
| Q4 2024 | -14.5% | -13.2% | -16.2% | |
| Q3 2024 | -2.5% | +0.0% | -1.7% | |
| Q2 2024 | +1.4% | +2.6% | +9.6% | |
| Q1 2024 | +3.2% | +6.1% | -11.4% | |
| Q4 2023 | +8.2% | +12.7% | +5.3% | |
| Q3 2023 | +23.5% | +41.6% | +79.8% | |
| Q2 2023 | +5.0% | -7.4% | -7.6% | |
| Q1 2023 | -6.1% | -10.3% | -12.5% | |
| Q4 2022 | -0.2% | -0.5% | -7.0% | |
| Q3 2022 | +7.3% | +5.5% | +7.1% | |
| Q2 2022 | +8.3% | +7.4% | -8.5% | |
| Q1 2022 | -32.7% | -41.8% | -55.3% | |
| Q4 2021 | +11.4% | +7.1% | +12.4% | |
| Q3 2021 | -3.6% | -6.5% | -19.1% | |
| Q2 2021 | -3.3% | -8.9% | -3.6% | |
| Q1 2021 | +6.8% | +9.1% | +15.7% | |
| Q4 2020 | -2.2% | +2.3% | -41.7% | |
| Q3 2020 | +8.7% | +14.6% | +32.2% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro